Aziz Mottiwala becomes RxSight CEO July 20 amid commercial challenges. The move follows the $200M Alcon deal for adjustable ...
OLN324 outperformed faricimab on anatomic outcomes as early as week 1 in the JADE trial, with no cases of intraocular ...
Lexitas Pharma Services and Ocusun have announced enrollment of the first patient in a pilot study evaluating ZOC2017217, an ...